OncoMatch/Clinical Trials/NCT06687941
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
Is NCT06687941 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies AST-201 for neoplasms.
Treatment: AST-201 — This is the first in human trial clinical study of AST-201 in patients with GPC3-positive advanced solid tumors. This study aims to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of AST-201 across various tumor types.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: GPC3 positive (positive)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-tumor treatment
Subjects with anti-tumor treatment within 4 weeks
Lab requirements
Blood counts
Adequate hematologic function
Kidney function
Adequate renal function
Liver function
Adequate hepatic function; Child-Pugh Class of A for HCC
Cardiac function
Adequate heart/coagulation function
Adequate hematologic, hepatic, renal, and heart/coagulation function; Child-Pugh Class of A for HCC
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify